

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT**  
**MENHYCIA® OBTAINS THE NOTIFICATION OF APPROVAL OF**  
**SUPPLEMENTAL DRUG APPLICATION**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that, the Company has obtained the Notification of Approval of Supplemental Drug Application (《藥品補充申請批准通知書》) issued by the National Medical Products Administration of China (the “**NMPA**”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “**MCV4**”, trade name: Menhycia®) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.

The Company’s Menhycia® is the first MCV4 vaccine product in China. Its launch has narrowed the gap between China and developed countries in this field and fulfilled the unmet demand of high-end vaccines in this field in China, and provided a superior solution for the prevention of meningococcal meningitis in children aged 6 and below. Leveraging its innovative advantage, Menhycia® has demonstrated strong market performance and achieved a continuous increase in market share.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, February 24, 2026

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.*